PTO/SB/08A (08-00)

March 1, 2002

1644

Pillarisetti, Sivaram

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Papergork Reduction Act of no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/091,357

**Filing Date** 

**Group Art Unit** 

First Named Inventor

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

**Examiner Name** Haddad, M. M. Sheet 1 of 2 Attorney Docket No. R18631 1050.1

	U.S. PATENT DOCUMENTS							
		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where		
Examiner Initials	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		· · · ·				<u> </u>		
						·		
	1							

	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Foreign Patent I	Document Kind Code (if known		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ•	
yn Ir	1	WO	94/04178		A1	Bio-Technology General Corp.	03-03-1994			

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 199

Substitute for Form 1449/A/PTO

Sheet 2

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

of 2

Co	mplete if Known	
Application Number	10/091,357	
Filing Date	March 1, 2002	
First Named Inventor	Pillarisetti, Sivaram	
Group Art Unit	1644	
Examiner Name	Haddad, M. M.	
Attorney Docket No.	R18631 1050.1	

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
MH	2	HALLORAN, B. et al., "Transforming Growth Factor-&1 Inhibits Human Arterial Smooth-Muscle Cell Proliferation in a Growth-Rate-Dependent Manner", The American Journal of Surgery, Aug. 1995, 193-197, Vol. 170, W. B. Saunders & Co.	
MH	3	KASSEN, A. et al., "Stromal Cells of the Human Prostate: Initial Isolation and Characterization", The Prostate, 1996, 89-97, Vol. 28, Wiley-Liss, Inc., New York, New York, U.S.A.	
MH	4	KRONEMANN, N. et al., "Growth-Inhibitory Effect of Cyclic GMP- and Cyclic AMP- dependent Vasodilators on Rat Vascular Smooth Muscle Cells: Effect on Cell Cycle and Cyclin Expression", British Journal of Pharmacology, Jan. 1999, 349-357, Vol. 126 (1), Stockton Press, United Kingdom	
mH	5	SCHRIEVER, C. et al., "Human Recombinant Insulin-Like Growth Factor I and -II Stimulate the Expression of Basic Fibroblast Growth Factor but Suppress the Division of Bovine Coronary Smooth Muscle Cells", Atherosclerosis, 1996, 255-263, Vol. 122 (2), Elsevier Science Ireland Ltd.	
WH-	6	PAHL, M. et al., "Antithrombin III Inhibits Mesangial Cell Proliferation", Journal of the American Society of Nephrology, 2249-2253, Vol. 7 (10), The American Society of Nephrology, U.S.A.	
			_
,			

Considered	Examiner Signature	Moher Haddacl	Date Considered	5/4/05
------------	-----------------------	---------------	--------------------	--------

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

#### COPY OF PAPERS ORIGINALLY FILED

ORIGINALLY FILED

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB contral with an original contains a valid OMB contral with a contain contain contains a valid OMB contral with a contain contain contains a valid OMB contral with a contain contain contains a valid OMB contral with a contain contain contain contains a valid OMB contral with a contain contain contain contains a valid OMB contral with a contain c

Complete if Known

Substitute for Form 1449/A/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 3

COL	Tologias Alleria
Application Numb r	10/091,357
Filing Date	March 1, 2002
First Named Inventor	Sivaram Pillarisetti MA
Group Art Unit	
Examiner Name	ASSA DAM METERY CENTER
Attorney Docket Number	18631-0141 (45176-268551)

	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2				
		Belknap, James K., et al., "Relationship Between Perlecan and Tropoelastin Gene	}				
	-	Expression and Cell Replication in the Developing Rat Pulmonary Vasculature", Am. J.					
		Respir. Cell Mol. Biol., Vol. 20, pp. 24-34 (1999)					
		Benitz, William E., et al., "Endothelial Heparan Sulfate Proteoglycan. I. Inhibitory					
		Effects on Smooth Muscle Cell Proliferation", Am. J. Respir. Cell Mol. Biol., Vol. 2,					
		pp.13-24 (1990)					
•		Bingley, John A., et al., "Inhibition of Neointimal Formation by Natural Heparan Sulfate					
		Proteoglycans of the Arterial Wall", Ann. N.Y. Acad. Sci., Vol. 811, pp. 238-244. (1997)	$\begin{bmatrix} & & & & & & & & & & & & & & & & & & &$				
		Brown, Christopher T., et al., "Characterization Of Proteoglycans Synthesized by	1				
		Cultured Corneal Fibroblasts in Response to Transforming Growth Factor Beta and Fetal					
		Galf Scrum", J. Biol. Chem., Vol. 274, No. 11, pp. 7111-7119 (1999)					
7		Bult, Hidde, "Restenosis: A Challenge for Pharmacology", Trends Pharmacol. Sci., Vol.					
		21, pp. 274-279 (2000)					
		Camphell, Julie H., et al., "Endothelial Cell Influences on Vascular Smooth Muscle					
.,		Phenotype", Ann. Rev. Physiol., Vol. 48, pp. 295-306 (1986)					
		Crowley, Stephen T., et al., "Multiple Growth Factors are Released from Mechanically					
		Injured Vascular Smooth Muscle Cells", Am. J. Physiol., Vol. 269, No. 5, pp. H1641- H1617 (1995)	-				
		Engelberg, Hyman, "Actions of Heparin in the Atherosclerotic Process", Am. Soc.					
		Pharm. Exp. Therap., Vol. 48, No. 2, pp.327-352 (1996)					
		Forsten, Kimberly E., et al., "Endothelial Proteoglycans Inhibit hFGF Binding and					
		Mitogenesis", J. Cell. Physiol., Vol. 172, pp. 209-220 (1997)					
		Fuji, Noriyasu, et al., "Thrombin Reduces Large Heparan Sulfate Proteoglycan					
:'2	<u>.</u>	Molecules in Cultured Vascular Endothelial Cell-Layers Through Inhibition of Core					
		Protein Synthesis", Thromb. Res., Vol. 88, pp. 299-307 (1997)					

Examiner Signature Maker Haddad Date Considered 5/4/65	un Haddad		
--	-----------	--	--

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

# COPY OF PAPERS ORIGINALLY FILED

_	COLLOCIMENO			
(PF "	ORIGINALLY FILED			
of 1945 ho persons erevenue	U.S. Patent and Trade	proved for use through 10/31/2002 to	OMB 0851-0031	n
		plete if Kn wn	ECEIVE	<b>.</b>
The state	Application Number	10/091,357	000	2
CHAPLE	Filing Date	March 1, 2002	MAY 1 6 400	L
LUSUKE	First Named Inventor	Sivaram Pillarisetti		
PLICANT	Group Art Unit		STATED IN	ſΓι
sary	Examiner Name	TFC	H CEMICIA,	, .
	Attorney Docket Number	18631-0141 (45115-26	8551)	
	of 1981 ho persons are record	ORIGINALLY FILED  U.S. Patent and Trade  U.S. Patent and Trade  U.S. Patent and Trade  Com  Application Number  Filling Date  First Named Inventor  Group Art Unit  Examiner Name	ORIGINALLY FILED  Approved for use through 10/31/2002  U.S. Patent and Trademark Office: U.S. DEPARTMENT OF 1984 the persons prestruired to respond to a collection of information unless it contains a valid OME  Complete If Kn wn  Application Number 10/091,357  Filing Date March 1, 2002  First Named Inventor Sivaram Pillarisetti  Group Art Unit  Examiner Name	ORIGINALLY FILED  PTO/SB/05B (08-00)  Approved for use through 10/31/2022 OM8 0851-0031  U.S. Patant and Trademark Office: U.S. DEPARTMENT OF COMMERCE  U.S. Patant and Trademark Office: U.S. DEPARTMENT OF COMMERCE  Complete If Kn wn  Application Number 10/091,357  Filling Date March 1, 2002 MAY 1 6 400  PLICANT  Group Art Unit  Examiner Name TECH CENTER  ON

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published	۲
		Garg, Uttam C., et al., "Nitric Oxide-Generating Vasodilators and 8-Bromo-Cyclic	
	_	Guanosine Monophosphete Inhibit Mitogenesis and Proliferation of Cultured Rat	
		Vascular Smooth Muscle Cells", J. Clin. Invest., Vol. 83, No. 5, pp.1774-1777 (1989)	]
		Hayashi, Kimiko, et al., "Endothelial Cells Interact with the Core Protein of Basement	F
		Membrane Perlecan Through Beta 1 and Beta 3 Integrins: An Adhesion Modulated by	l
		Glycosaminoglycan", J. Cell Biol., Vol. 119, No. 4, pp. 945-959 (1992)	
		Iozzo, Renato V, et al., "Structural Characterization of Perlecan Gene Promoter", J.	F
		Riol. Chem., Vol. 272, No. 8, pp. 5219-5228 (1997).	
		Iozzo, Renato V., et al., "The Biology of Perlecan: the Multi-faceted Heparan Sulphate	Γ
MM	14	Proteoglycan of Basement Membranes and Pericellular Matrices", Biochem. J., Vol.	
'''	_ '+	302, pp. 625-639 (1994)	
		Karnovsky, Morris J., "EndothelialVascular Smooth Muscle Cell Interactions", Am. J.	F
		Pathol., Vol. 105, No. 3, pp.200-206 (1981)	
	1	Karnovsky, M.J., et al., "Heparin, Heparan Sulfate, Smooth Muscle Cells, and	
mΗ	16	Atherosclerosis", Ann. N.Y. Acad. Sci., Vol. 556, pp. 268-281 (1989)	
		Koyama, Noriyuki, et al., "Heparan Sulfate Proteoglycans Mediate a Potent Inhibitory	
		Signal for Migration of Vascular Smooth Muscle Cells", Circ. Res., Vol. 83, No. 3, pp.	7
		305-313 (1998)	
		Luscher, Thomas F, et al., "The Pathogenesis Of Cardiovascular Disease: Role of the	
		Endothelium as a Target and Mediator", Atheroselerosis 118 Suppl., pp. S81-S90 (1995)	
		Nugent, Matthew A., et al., "Perlecan is Required to Inhibit Thrombosis After Deep	_
		Vascular Injury and Contributes to Endothelial Cell-Mediated Inhibition of Intimal	
		Hyperplasia", PNAS, Vol. 97, No. 12, pp. 6722-6727 (2000)	
		Orford, James L., et al.; "The Comparative Pathobiology of Atherosclerosis and	_
		Restenosis", Am. J. Cardiol., Vol. 86. pp. 6H-11H (2000)	
		Ottlinger, Michael E., et al., "Heparin Inhibits Mitogen-Activated Protein Kinase	
		Activation in Intact Rat Vascular Smooth Muscle Cells", J. Biol. Chem., Vol. 268, No.	
ļ	- 1	<del>- 26, pp.19173-19176 (1993)</del>	

	Examiner Signature	Maker	Haddad	Date Considered	5	-/4	1/05
--	-----------------------	-------	--------	--------------------	---	-----	------

<b>COPY OF</b>	PAPERS
ORIGINAL	LY FILED

1.			01	r 6.	COPY OF PAPERS			
. • •	Hadae the Panag	und Par	MAY 1 3	2002 marij		pproved for use through 10/3 emark Office: U.S. DEPARTI mation unless it contains a va		•
(2)			Cot	npl te if Known	-CEIVE	ノ し		
Substitute f	or Form 1449/A/PTO		PADEM	ok off	Application Number	10/091,357	BEOF	
	NEODMAT	ION	DICCI OCLIDI	Ani	Filing Date	March 1, 2002	c 200	2
-		_	DISCLOSURI		First Named Inventor	Sivaram Pillaris	etti MAY To Lo	_
;	STATEMEN	IT B'	Y APPLICANI	ſ	Group Art Unit			שעוטנ
	`(use as ma	any sheel	s as necessary		Examiner Name		OFNITER 18	MIC
Sheet	3	of 3			Attorney Docket Number	18631-0141 (451	T3-268.56Y)	

		OTHER INFORMATION, NON DATENT LITERATURE COCCUMENTS						
Examiner Initials	Cite No.	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
		Paka, Latha, er ul., "Perlecan Mediates the Antiproliferative Effect of Apolipoprotein E on Smooth Muscle Cells: An Underlying Mechanism for the Modulation of Smooth						
		Muscle Cell Growth?", J. Biol. Chem., Vol. 274, No. 51, pp. 36403-36408 (1999)						
		Paka, Latha, et al., "Apolipoprotein E Containing High Density Lipoprotein Stimulates						
	,	Endothelial Production Heparan Sulfate Rich in Biologically Active Heparin-Like Domains", J. Biol. Chem., Vol. 274, No. 8, pp. 4816-4823 (1999)						
	1	Pillarisetti, Sivaram, et al., "Lysolecithin-induced Alteration of Subendothelial Heparan	ļ -					
	1	Sulfate Proteoglycans Increases Monocyte Binding to Matrix", J. Biol. Chem., Vol. 270, No. 50, pp. 29760-29765 (1995)						
	7	Pillarisetti, Sivaram, et al., "Subendothelial Retention of Lipoprotein (a): Evidence that Reduced Heperan Sulfate Promotes Lipoprotein Binding By Subendothelial Matrix", J. etin. Invest., Vol. 100, No. 4, pp. 867-874 (1997)						
		Ramasamy, Santhini, et al., "Oxidized Lipid-Mediated Alterations In Proteoglycan-Metabolism In Cultured Pulmonary Endothelial Cells", Atherosclerosis 120, pp. 199-208 (1996)						
	,	Rosenberg, Robert D., et al., "Heparan Sulfate Proteoglycans of Vascular System: Specific Structures Emerge But How is Synthesis Regulated?", J. Clin. Invest., Vol. 99, -No. 9, pp. 2062-2070 (1997)						
	<del>- /</del>	Schwartz, Stephen M., "Smooth Muscle Migration in Atherosclerosis and Restenosis", J. Clin. Invest., Vol. 99, No. 12, pp. 2814-2817 (1997)						
-	7	Weiser, Mary C., et al., "Developmental Regulation of Perlecan Gene Expression in Aortic Smooth Muscle Cells", J. Matrix Biol., Vol. 15, No. 5, pp. 331-340 (1996)						
		Yu, Sheu-Meei, et al., "cGMP-elevating Agents Suppress Proliferation of Vascular Smooth Muscle Cells by Inhibiting the Activation of Epidermal Growth Factor Signaling-Pathway", Circulation, Vol. 95, No. 5, pp. 1269-1277 (1997)						

Examiner Signature	Jahu	Haddad	Date Considered	 5/4	1/0	55
	 			, ,	,	

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.